DE60023167D1 - Pyrazol-derivate als cannabinoidrezeptor-antagonisten - Google Patents
Pyrazol-derivate als cannabinoidrezeptor-antagonistenInfo
- Publication number
- DE60023167D1 DE60023167D1 DE60023167T DE60023167T DE60023167D1 DE 60023167 D1 DE60023167 D1 DE 60023167D1 DE 60023167 T DE60023167 T DE 60023167T DE 60023167 T DE60023167 T DE 60023167T DE 60023167 D1 DE60023167 D1 DE 60023167D1
- Authority
- DE
- Germany
- Prior art keywords
- receptor antagonists
- cannabinoid receptor
- pyrazol derivatives
- pyrazol
- derivatives
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Virology (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Ophthalmology & Optometry (AREA)
- Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Child & Adolescent Psychology (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US15999399P | 1999-10-18 | 1999-10-18 | |
PCT/US2000/041239 WO2001029007A1 (en) | 1999-10-18 | 2000-10-18 | Pyrazole derivatives as cannabinoid receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
DE60023167D1 true DE60023167D1 (de) | 2006-02-23 |
DE60023167T2 DE60023167T2 (de) | 2006-06-14 |
Family
ID=22575021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60023167T Expired - Fee Related DE60023167T2 (de) | 1999-10-18 | 2000-10-18 | Pyrazol-derivate als cannabinoidrezeptor-antagonisten |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP1224173B1 (de) |
JP (1) | JP2003512357A (de) |
AU (1) | AU780572B2 (de) |
CA (1) | CA2387892A1 (de) |
DE (1) | DE60023167T2 (de) |
MX (1) | MXPA02005100A (de) |
WO (1) | WO2001029007A1 (de) |
Families Citing this family (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69910373T2 (de) | 1998-05-04 | 2004-04-01 | The University Of Connecticut, Farmington | Analgetische und immunomodulierende cannabinoiden |
US6900236B1 (en) | 1999-10-18 | 2005-05-31 | University Of Connecticut | Cannabimimetic indole derivatives |
DE60033834T2 (de) | 1999-10-18 | 2007-11-15 | The University Of Connecticut, Farmington | Für periphäre cannabinoid-rezeptoren selektive liganden |
US6943266B1 (en) | 1999-10-18 | 2005-09-13 | University Of Connecticut | Bicyclic cannabinoid agonists for the cannabinoid receptor |
US7393842B2 (en) * | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
AU2002319627A1 (en) | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
CA2468794A1 (en) * | 2001-12-07 | 2003-06-19 | Virginia Commonwealth University | Treatment of neoplasia |
FR2838438A1 (fr) * | 2002-04-11 | 2003-10-17 | Sanofi Synthelabo | Derives de diphenylpyridine,leur preparation, les compositions pharmaceutiques en contenant |
AU2003250117B2 (en) * | 2002-07-29 | 2007-05-10 | F. Hoffmann-La Roche Ag | Novel benzodioxoles |
CN1678303A (zh) | 2002-08-23 | 2005-10-05 | 康涅狄格大学 | 具有治疗作用的酮类大麻类 |
US7319110B2 (en) * | 2002-09-19 | 2008-01-15 | Solvay Pharmaceuticals B.V. | 1H-1,2,4-triazole-3-carboxamide derivatives having cannabinoid-CB1 receptor agonistic, partial agonistic, inverse agonistic or antagonistic activity |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
AR043633A1 (es) | 2003-03-20 | 2005-08-03 | Schering Corp | Ligandos de receptores de canabinoides |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
CN1832741A (zh) * | 2003-08-07 | 2006-09-13 | 默克公司 | 作为11-β-羟甾类脱氢酶-1抑制剂的吡唑甲酰胺类 |
US20100222316A1 (en) | 2004-04-29 | 2010-09-02 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US8415354B2 (en) | 2004-04-29 | 2013-04-09 | Abbott Laboratories | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
US7880001B2 (en) | 2004-04-29 | 2011-02-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
ITMI20041032A1 (it) | 2004-05-24 | 2004-08-24 | Neuroscienze S C A R L | Compositi farmaceutici |
WO2006017892A1 (en) * | 2004-08-16 | 2006-02-23 | Northern Sydney And Central Coast Area Health Service | Methods for improving cognitive functioning |
JP2008517976A (ja) | 2004-10-25 | 2008-05-29 | ゾルファイ ファーマスーティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb1カンナビノイド受容体拮抗薬及びカリウムチャンネルオープナーから成る、真性糖尿病1型、肥満及び関連症状の治療用の医薬組成物 |
US20090192198A1 (en) | 2005-01-05 | 2009-07-30 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
KR101496206B1 (ko) | 2005-01-05 | 2015-02-27 | 애브비 인코포레이티드 | 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제로서의 아다만틸 유도체 |
US8198331B2 (en) | 2005-01-05 | 2012-06-12 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
EP2835367A1 (de) | 2005-01-05 | 2015-02-11 | AbbVie Inc. | Inhibitoren des 11-Beta-Hydroxysteroid-Dehydrogenase-1-Enzyms |
AU2006205220B2 (en) * | 2005-01-10 | 2012-09-13 | Exelixis, Inc. | Heterocyclic carboxamide compounds as steroid nuclear receptors ligands |
WO2006074445A2 (en) * | 2005-01-10 | 2006-07-13 | Alexandros Makriyannis | Novel heteropyrrole analogs acting on cannabiniod receptors |
GB0514738D0 (en) * | 2005-07-19 | 2005-08-24 | Astrazeneca Ab | Therapeutic agents |
JP2009519349A (ja) | 2005-12-15 | 2009-05-14 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を変調する化合物 |
WO2007107470A2 (en) | 2006-03-22 | 2007-09-27 | F. Hoffmann-La Roche Ag | Pyrazoles as 11-beta-hsd-1 |
WO2008014199A2 (en) | 2006-07-28 | 2008-01-31 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the cb2 receptor |
KR20090069318A (ko) | 2006-09-25 | 2009-06-30 | 베링거 인겔하임 인터내셔날 게엠베하 | Cb2 수용체를 조절하는 화합물 |
US8148404B2 (en) | 2006-12-18 | 2012-04-03 | 7Tm Pharma A/S | Modulators of CB1 receptors |
JP5736098B2 (ja) | 2007-08-21 | 2015-06-17 | アッヴィ・インコーポレイテッド | 中枢神経系障害を治療するための医薬組成物 |
KR20100072037A (ko) | 2007-09-20 | 2010-06-29 | 애보트 헬스케어 프로덕츠 비.브이. | 칸나비노이드 cb₁수용체 효능제로서의 5-아릴-4,5-디하이드로-(1h)-피라졸 |
KR20110063438A (ko) | 2008-09-25 | 2011-06-10 | 베링거 인겔하임 인터내셔날 게엠베하 | Cb2 수용체를 선택적으로 조절하는 설포닐 화합물 |
WO2010079241A1 (es) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
EP2523936A1 (de) | 2010-01-15 | 2012-11-21 | Boehringer Ingelheim International GmbH | Cb2 rezeptor-modulierende verbindungen |
US8846936B2 (en) | 2010-07-22 | 2014-09-30 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the CB2 receptor |
FR2978660B1 (fr) * | 2011-08-05 | 2013-09-20 | Oreal | Utilisation d'antagoniste du recepteur cb1 en tant qu'agent blanchissant et/ou anti-brunissement des matieres keratiniques |
RU2014141674A (ru) | 2012-03-16 | 2016-05-10 | Аксикин Фармасьютикалз, Инк. | 3,5-диаминопиразоловые ингибиторы киназы |
JO3215B1 (ar) | 2012-08-09 | 2018-03-08 | Phenex Pharmaceuticals Ag | حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy |
EP2803668A1 (de) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Neuartige (Cyano-dimethyl-methyl)-isoxazole und -[1,3,4]-thiadiazole |
NZ631142A (en) | 2013-09-18 | 2016-03-31 | Axikin Pharmaceuticals Inc | Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors |
KR102034202B1 (ko) | 2014-12-23 | 2019-10-18 | 에스엠에이 세라퓨틱스 아이엔씨. | 3,5-디아미노피라졸 키나제 억제제 |
BR112020003725A2 (pt) | 2017-10-06 | 2020-11-03 | Forma Therapeutics, Inc. | inibição da peptidase 30 específica de ubiquitina |
JP7449242B2 (ja) | 2018-05-17 | 2024-03-13 | フォーマ セラピューティクス,インコーポレイテッド | ユビキチン特異的ペプチダーゼ30(usp30)阻害剤として有用な縮合二環化合物 |
SI3860989T1 (sl) | 2018-10-05 | 2023-06-30 | Forma Therapeutics, Inc. | Kondenzirani pirolini,ki delujejo kot zaviralci ubikvitin-specifične proteaze (usp30) |
GB2602019A (en) * | 2020-12-15 | 2022-06-22 | Gw Res Ltd | Cannabinoid derivative as a pharmaceutically active compound and method of preparation thereof |
GB202208810D0 (en) * | 2022-06-15 | 2022-07-27 | Gw Res Ltd | Crystaline forms of a synthetic cannabinoid |
WO2024026359A1 (en) * | 2022-07-26 | 2024-02-01 | The Board Of Trustees Of The University Of Illinois | Compounds and methods for the treatment of diseases associated with parasitic worms |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2692575B1 (fr) * | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
FR2714057B1 (fr) * | 1993-12-17 | 1996-03-08 | Sanofi Elf | Nouveaux dérivés du 3-pyrazolecarboxamide, procédé pour leur préparation et compositions pharmaceutiques les contenant. |
FR2742148B1 (fr) * | 1995-12-08 | 1999-10-22 | Sanofi Sa | Nouveaux derives du pyrazole-3-carboxamide, procede pour leur preparation et compositions pharmaceutiques les contenant |
US5760225A (en) * | 1996-11-15 | 1998-06-02 | Neurogen Corporation | Certain pyrazole derivatives as corticotropin-releasing factor receptor CRF1 specific ligands |
EP1176140B1 (de) * | 1999-02-10 | 2004-12-29 | Mitsubishi Pharma Corporation | Amid-derivate und deren medizinische verwendung |
-
2000
- 2000-10-18 CA CA002387892A patent/CA2387892A1/en not_active Abandoned
- 2000-10-18 EP EP00982694A patent/EP1224173B1/de not_active Expired - Lifetime
- 2000-10-18 DE DE60023167T patent/DE60023167T2/de not_active Expired - Fee Related
- 2000-10-18 AU AU19689/01A patent/AU780572B2/en not_active Ceased
- 2000-10-18 MX MXPA02005100A patent/MXPA02005100A/es active IP Right Grant
- 2000-10-18 WO PCT/US2000/041239 patent/WO2001029007A1/en active IP Right Grant
- 2000-10-18 JP JP2001531807A patent/JP2003512357A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
DE60023167T2 (de) | 2006-06-14 |
EP1224173B1 (de) | 2005-10-12 |
EP1224173A4 (de) | 2002-11-20 |
EP1224173A1 (de) | 2002-07-24 |
CA2387892A1 (en) | 2001-04-26 |
MXPA02005100A (es) | 2003-09-25 |
WO2001029007A1 (en) | 2001-04-26 |
AU780572B2 (en) | 2005-04-07 |
AU1968901A (en) | 2001-04-30 |
JP2003512357A (ja) | 2003-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60023167D1 (de) | Pyrazol-derivate als cannabinoidrezeptor-antagonisten | |
ATE253067T1 (de) | Diazabicyloderivate als nikotin-acetylcholin- rezeptorliganden | |
ATE384053T1 (de) | Triazolderivate als tachykininrezeptor- antagonisten | |
DE60218340D1 (de) | 5,6-diaryl-pyrazineamidderivate als cb1 antagonisten | |
DE60120419D1 (de) | 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten | |
ATE288898T1 (de) | Phenylethenyl- oder phenylethinylderivate als glutamatrezeptorantagonisten | |
DE60022386D1 (de) | Substituierte imidazole als neuropeptide y y5 rezeptor antagonisten | |
DE60032601D1 (de) | Als antikrebsmittel verwendbare heterocyklische derivate | |
DE69939053D1 (de) | 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives als muskarin-rezeptor antagonisten | |
ATE416173T1 (de) | 1-(3 -heteroarylpropyl- oder -prop -2-enyl) -4- benzylpiperidine als nmda-rezeptor-antagonisten | |
ATE338021T1 (de) | Substituierte 2-dialkylaminoalkylbiphenyl- derivate | |
ATE221052T1 (de) | Tetrahydrochinolinderivate als eaa antagonisten | |
DE60114852D1 (de) | Chinazolin-derivate als alpha-1 adrenerge antagonisten | |
NO20013997L (no) | Reseptoranalyse | |
DE60316411D1 (de) | Thiazolderivate als npy-rezeptorantagonisten | |
ATE254621T1 (de) | Thienoisoxazolyl- und thienylpyrazolyl-phenoxy substituierte propyl derivate als d4 antagonisten | |
ATE244716T1 (de) | Neue n-triazolylmethyl-piperazinderivate als neurokininrezeptor-antagonisten | |
DE60017110D1 (de) | Biphenylderivate als neurokinin-1 antagonisten | |
DE50008020D1 (de) | Substituierte pyrrolidin-2,3,4-trion-derivate wirksam als nmda-rezeptor-antagonisten | |
ATE338043T1 (de) | 5-methoxy-8-aryl- 1,2,4ötriazolo 1,5-aöpyridine derivative als adenosin-rezeptor antagonisten | |
DE69703242D1 (de) | Indolin-derivate verwendbar als 5-ht-2c rezeptor-antagonisten | |
DE60003072D1 (de) | Thiazolidindion-derivate als antidiabetika | |
ATE281456T1 (de) | Aminotriazolopyridinderivate als adenosinrezeptorliganden | |
DE60113525D1 (de) | Propansäure-derivate als integrin-rezeptor-antagonisten | |
DE69717449D1 (de) | Indolin-derivate verwendbar als 5-ht-2c rezeptor-antagonisten |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition | ||
8339 | Ceased/non-payment of the annual fee |